Trial reportEuropean journal of nuclear medicine and molecular imaging2025
Safety and dosimetry of [
Trial report in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04711135 (A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)
Who cites it
14 citing papers in PubMed.
- Fraction-dependent dose dynamics and clinical safety in high-risk neuroblastoma treated with [European journal of nuclear medicine and molecular imaging · 2026Trial
- The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [Journal of neuroendocrinology · 2026Trial
- Radioligand therapy for pediatric patients with solid tumors.The British journal of radiology · 2026Review
- SSTR2 receptor states and cellular metabolism modulateEANM innovation · 2026Article
- Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non-Clinical Evidence, and Regulatory Science.Journal of clinical pharmacology · 2026Review
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Functional profiling of somatostatin receptors identifies somatostatin receptor subtype 2 as a vulnerability in Succinate Dehydrogenase SDHB-deficient pheochromocytomas and paragangliomas.Molecular biomedicine · 2026Article
- Radioligand Therapy and Sequencing in Gastroenteropancreatic Neuroendocrine Tumors: A Patient Perspective Review.JCO oncology practice · 2026Review
- Management of Peptide Receptor Radionuclide Therapy Toxicities in Neuroendocrine Neoplasm Patients.Current treatment options in oncology · 2026Review
- Future of radiotheranostics.BMJ oncology · 2026Review
- Review
- Review
- Gastroenteropancreatic neuroendocrine neoplasms in children and adults: a comparative review.Frontiers in endocrinology · 2025Review
- Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade.Frontiers in nuclear medicine · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
19 authors.
Funding
Abstract
purposeNETTER-P, an open-label Phase II study, evaluated the safety and dosimetry of [
methodsPatients (12-17 years old) received four cycles of
resultsEleven patients (4 GEP-NET, 7 PPGL; median age 15 [range, 13-17] years) were enrolled and received ≥ 1 administration of
conclusionNo new safety signals attributable to
trial registrationClinicalTrials.gov, NCT04711135. Registered 15 January 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.